NASDAQ$ARCT
Arcturus Therapeutics Holdings Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported a net loss with a slight decrease in revenue due to lower milestone achievement from the CSL agreement, offset by KOSTAIVE sales and increased BARDA revenue.
Arcturus Therapeutics reported its Q3 2024 financial results, featuring a revenue of $41.7 million and a net loss of $6.9 million, or ($0.26) per diluted share. The company achieved a $25 million commercial milestone with the first sale of KOSTAIVE® in Japan and anticipates another milestone related to potential European approval in the first quarter of 2025. The company's cash runway is expected to extend through the first quarter of fiscal year 2027.
- Achieved $25 million commercial milestone with first KOSTAIVE® sale in Japan.
- Phase 2 studies for Cystic Fibrosis and OTC Deficiency on track for POC data in first half of 2025.
- KOSTAIVE® European CHMP opinion expected in December.
- Net loss of $6.9 million, or ($0.26) per diluted share, for Q3 2024.
Headline financials
Revenue & EPS history
Arcturus Therapeutics · Revenue · Quarterly
$41.7M
Forward guidance
Arcturus anticipates another milestone related to potential European approval in the first quarter of 2025 and expects its cash runway to extend through the first quarter of fiscal year 2027.
Tailwinds
- Potential European approval milestone expected in Q1 2025.
- Cash runway extends through Q1 2027.
- Phase 2 studies for Cystic Fibrosis and OTC Deficiency on track for POC data in first half of 2025.
- KOSTAIVE® European CHMP opinion expected in December.
- Positive Phase 3 results support KOSTAIVE® U.S. BLA filing in H1 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-3.8%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-3.0%
Avg return
30 days after
38%
18 / 48 earnings
Positive
+27.3%
Q4 2022
Best reaction
-53.9%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.7% | -9.7% | -20.0% | |
| Q4 2025 | -5.2% | -7.0% | +1.5% | |
| Q3 2025 | -1.1% | -17.2% | -14.4% | |
| Q1 2025 | +2.3% | +0.5% | +9.1% | |
| Q4 2024 | -8.9% | -10.7% | -43.0% | |
| Q3 2024 | +7.1% | +6.8% | +4.1% | |
| Q2 2024 | -3.5% | -12.0% | -7.3% | |
| Q1 2024 | -2.8% | +4.2% | +15.5% | |
| Q4 2023 | -2.4% | +2.4% | -15.4% | |
| Q3 2023 | +27.2% | +41.1% | +58.3% | |
| Q2 2023 | -20.0% | -13.6% | -0.2% | |
| Q1 2023 | +3.1% | +7.2% | -0.5% | |
| Q4 2022 | +27.3% | +51.2% | +63.6% | |
| Q3 2022 | -14.9% | -20.1% | -25.9% | |
| Q2 2022 | -16.8% | -8.8% | -28.1% | |
| Q1 2022 | -11.4% | -9.3% | +4.0% | |
| Q4 2021 | -6.6% | -20.3% | +16.5% | |
| Q3 2021 | -3.1% | +0.5% | +5.2% | |
| Q2 2021 | +2.6% | -2.6% | +12.8% | |
| Q1 2021 | -14.4% | -9.2% | +7.2% | |
| Q4 2020 | +2.4% | -18.0% | -21.6% | |
| Q3 2020 | -37.8% | -25.1% | +40.5% | |
| Q2 2020 | -14.4% | -16.2% | -31.3% | |
| Q1 2020 | -5.2% | +11.9% | -21.1% | |
| Q4 2019 | -26.9% | -9.8% | +12.2% | |
| Q3 2019 | -3.1% | -0.3% | +6.9% | |
| Q2 2019 | +16.0% | +16.2% | +16.6% | |
| Q3 2018 | -4.2% | -10.6% | -38.8% | |
| Q1 2018 | -2.9% | -6.7% | +1.6% | |
| Q4 2017 | -6.6% | -5.3% | -39.3% | |
| Q3 2017 | -3.3% | -4.6% | -5.3% | |
| Q2 2017 | +2.0% | +0.0% | +4.9% | |
| Q1 2017 | +3.6% | +4.5% | +2.7% | |
| Q4 2016 | +5.2% | +13.8% | -50.5% | |
| Q3 2016 | +0.8% | -4.2% | -30.8% | |
| Q2 2016 | +3.4% | +5.5% | +2.1% | |
| Q1 2016 | -10.0% | — | — | |
| Q4 2015 | -6.2% | — | — | |
| Q3 2015 | -16.8% | — | — | |
| Q2 2015 | +13.8% | — | — | |
| Q1 2015 | -0.5% | — | — | |
| Q4 2014 | +1.6% | — | — | |
| Q3 2014 | -53.9% | — | — | |
| Q2 2014 | +5.4% | — | — | |
| Q1 2014 | -0.2% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q3 2013 | -3.2% | — | — | |
| Q2 2013 | +1.2% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro